Ken Griffin Innoviva, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Innoviva, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 12,600 shares of INVA stock, worth $238,139. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,600

Previous 20,000 37.0%

Holding current value

$238,139

Previous $328,000 25.91%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$16.33 - $20.04 $6.32 Million - $7.76 Million	387,005 Added 377.75%	489,455 $9.45 Million
Q2 2024 Aug 14, 2024	BUY	$14.4 - $16.4 $378,187 - $430,713	26,263 Added 34.47%	102,450 $1.68 Million
Q1 2024 May 15, 2024	SELL	$14.56 - $16.78 $2.99 Million - $3.45 Million	-205,617 Reduced 72.96%	76,187 $1.16 Million
Q4 2023 Feb 14, 2024	BUY	$12.32 - $16.27 $1.24 Million - $1.63 Million	100,256 Added 55.22%	281,804 $4.52 Million
Q3 2023 Nov 14, 2023	SELL	$12.37 - $13.89 $6.81 Million - $7.65 Million	-550,859 Reduced 75.21%	181,548 $2.36 Million
Q2 2023 Aug 14, 2023	SELL	$11.39 - $13.72 $1.32 Million - $1.59 Million	-116,220 Reduced 13.7%	732,407 $9.32 Million
Q1 2023 May 15, 2023	SELL	$10.73 - $13.6 $1.47 Million - $1.86 Million	-136,912 Reduced 13.89%	848,627 $9.55 Million
Q4 2022 Feb 14, 2023	BUY	$11.8 - $13.78 $1.74 Million - $2.03 Million	147,595 Added 17.61%	985,539 $13.1 Million
Q3 2022 Nov 14, 2022	BUY	$11.61 - $15.22 $2.76 Million - $3.62 Million	237,602 Added 39.58%	837,944 $9.73 Million
Q2 2022 Aug 15, 2022	BUY	$14.32 - $19.88 $2.08 Million - $2.89 Million	145,364 Added 31.95%	600,342 $8.86 Million
Q1 2022 May 16, 2022	BUY	$15.39 - $20.25 $6.47 Million - $8.52 Million	420,636 Added 1224.84%	454,978 $8.8 Million
Q4 2021 Feb 14, 2022	SELL	$15.91 - $18.72 $5.67 Million - $6.67 Million	-356,537 Reduced 91.21%	34,342 $592,000
Q3 2021 Nov 15, 2021	BUY	$13.06 - $17.24 $2.19 Million - $2.9 Million	168,057 Added 75.42%	390,879 $6.53 Million
Q2 2021 Aug 16, 2021	SELL	$11.45 - $13.96 $677,885 - $826,487	-59,204 Reduced 20.99%	222,822 $2.99 Million
Q1 2021 May 17, 2021	BUY	$11.06 - $12.87 $56,240 - $65,443	5,085 Added 1.84%	282,026 $3.37 Million
Q4 2020 Feb 16, 2021	SELL	$9.33 - $12.48 $841,108 - $1.13 Million	-90,151 Reduced 24.56%	276,941 $3.43 Million
Q3 2020 Nov 16, 2020	BUY	$10.33 - $14.49 $1.29 Million - $1.81 Million	124,689 Added 51.44%	367,092 $3.84 Million
Q2 2020 Aug 14, 2020	SELL	$11.49 - $15.26 $5.48 Million - $7.28 Million	-477,337 Reduced 66.32%	242,403 $3.39 Million
Q1 2020 May 15, 2020	BUY	$8.11 - $15.23 $1.04 Million - $1.94 Million	127,653 Added 21.56%	719,740 $8.46 Million
Q4 2019 Feb 14, 2020	SELL	$10.28 - $14.38 $2.39 Million - $3.34 Million	-232,596 Reduced 28.2%	592,087 $8.38 Million
Q3 2019 Nov 14, 2019	BUY	$10.05 - $14.55 $5.21 Million - $7.54 Million	517,911 Added 168.83%	824,683 $8.69 Million
Q2 2019 Aug 14, 2019	BUY	$13.1 - $14.95 $66,286 - $75,647	5,060 Added 1.68%	306,772 $4.47 Million
Q1 2019 May 15, 2019	BUY	$13.69 - $20.06 $2.18 Million - $3.19 Million	159,016 Added 111.44%	301,712 $0
Q4 2018 Feb 14, 2019	BUY	$13.96 - $18.26 $1.8 Million - $2.35 Million	128,797 Added 926.66%	142,696 $2.49 Million
Q2 2018 Aug 10, 2018	BUY	$13.44 - $17.59 $16,746 - $21,917	1,246 Added 9.85%	13,899 $0
Q1 2018 May 11, 2018	SELL	$13.8 - $16.99 $106,839 - $131,536	-7,742 Reduced 37.96%	12,653 $211,000
Q4 2017 Feb 09, 2018	SELL	$11.73 - $14.75 $1.64 Million - $2.07 Million	-140,061 Reduced 87.29%	20,395 $289,000
Q3 2017 Nov 09, 2017	BUY	$12.06 - $14.12 $1.94 Million - $2.27 Million	160,456	160,456 $2.27 Million

Others Institutions Holding INVA

# of Institutions

229

Shares Held

79.2M

Call Options Held

37.6K

Put Options Held

300

View Full List

About Innoviva, Inc.

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.32B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

More about INVA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account